Hind.Bio Science

Who are the top shareholders of the Hind.Bio Science?

The top shareholder of Hind.Bio Science is promoter Venkata Rama Mohan Raju Jampana with 9.39%, followed by public shareholder Satyasai Kolli at 2.59%. Individual investors hold a substantial 84.02% of the shares, with no pledged promoter holdings or mutual fund/foreign institutional investor holdings.

The top shareholders of Hind.Bio Science include Venkata Rama Mohan Raju Jampana, who is the promoter with the highest holding at 9.39%. The highest public shareholder is Satyasai Kolli, holding 2.59%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 84.02% of the shares. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings.

What does Hind.Bio Science do?

Hindustan Bio Sciences Ltd manufactures and sells pharmaceutical products and operates in the software products industry. As of March 2025, it reported net sales and profit of 0 Cr, with a market cap of Rs 10 Cr.

Overview:<BR>Hindustan Bio Sciences Ltd is engaged in the manufacturing and sale of pharmaceutical products, operating within the software products industry and classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated as a Public Limited Company on December 16, 1991, and was formerly known as Hindustan Softel Ltd. It commenced operations in 1992 and the latest quarterly results reported net sales and net profit of 0 Cr for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 10 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 10.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 2.15 <BR>Return on Equity: 30.00% <BR>Price to Book: 9.99<BR><BR>Contact Details:<BR>Address: H No 8-2-269/S PlotNo 31 RdNo2, Sagar Co-Op Hous Banjara Hills Hyderabad Telangana : 500034 <BR>Tel: 91-40-23555161/23555181 <BR>Email: pharma.hindustanbio@gmail.com <BR>Website: http://www.hindustanbiosciences.in

Who are in the management team of Hind.Bio Science?

As of March 2022, the management team of Hind.Bio Science includes J.V.R. Mohan Raju (Chairman & Managing Director), B R Rao, J Uma, K Rama Chandra Raju, and M Satyanarayana Raju (all Independent Directors), who guide the company's strategic direction and governance.

As of March 2022, the management team of Hind.Bio Science includes:<BR><BR>1. J.V.R. Mohan Raju - Chairman & Managing Director<BR>2. B R Rao - Independent Director<BR>3. J Uma - Director<BR>4. K Rama Chandra Raju - Independent Director<BR>5. M Satyanarayana Raju - Independent Director<BR><BR>These individuals play key roles in guiding the company's strategic direction and governance.

Has Hind.Bio Science declared dividend?

No Dividend History Available

Who are the peers of the Hind.Bio Science?

Hind.Bio Science's peers include Oracle Fin.Serv., C.E. Info System, Tanla Platforms, Moschip Tech., Nucleus Soft., First Fintec, CLIO Infotech, Virgo Global, and Nihar Info Glob. While Oracle Fin.Serv. shows excellent management and capital structure, Hind.Bio Science and most peers exhibit below-average growth and capital structure, with Hind.Bio Science achieving a 1-year return of 19.58%.

Peers: The peers of Hind.Bio Science are Oracle Fin.Serv., C.E. Info System, Tanla Platforms, Moschip Tech., Nucleus Soft., First Fintec, CLIO Infotech, Virgo Global, and Nihar Info Glob.<BR><BR>Quality Snapshot: Excellent management risk is observed at Oracle Fin.Serv. and the rest have Below Average management risk, including Hind.Bio Science, First Fintec, Moschip Tech., Virgo Global, Nihar Info Glob. Good growth is noted at C.E. Info System and Tanla Platforms, while Hind.Bio Science, First Fintec, Moschip Tech., Nucleus Soft., Virgo Global, and Nihar Info Glob. exhibit Below Average growth. Excellent capital structure is seen at Oracle Fin.Serv., C.E. Info System, Tanla Platforms, and Nucleus Soft., while Hind.Bio Science, First Fintec, Moschip Tech., Virgo Global, and Nihar Info Glob. have Below Average capital structure, and CLIO Infotech does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Oracle Fin.Serv. at 10.09%, while the peer with the lowest is Tanla Platforms at -32.80%. Hind.Bio Science has a 1-year return of 19.58%, which is higher than both Tanla Platforms and Virgo Global. Additionally, the six-month return is negative for Oracle Fin.Serv., Tanla Platforms, Moschip Tech., Virgo Global, and First Fintec.

What is the technical trend for Hind.Bio Science?

As of June 2, 2025, Hind.Bio Science shows a mildly bearish trend overall, with mixed signals from indicators suggesting some weekly strength but monthly weakness.

As of 2 June 2025, the technical trend for Hind.Bio Science has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD shows a mildly bullish signal, contrasting with the monthly MACD which is mildly bearish. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting some upward pressure. However, the KST indicates a mildly bullish trend weekly but is mildly bearish monthly. Overall, the mixed signals from the indicators suggest a mildly bearish stance with some strength in the weekly timeframe but overall weakness in the monthly perspective.

How big is Hind.Bio Science?

As of 24th July, Hindustan Bio Sciences Ltd has a market capitalization of 9.00 Cr, with recent net sales of 0.79 Cr and a net profit of 0.10 Cr. The company's shareholder's funds are 0.80 Cr, and total assets amount to 3.37 Cr.

As of 24th July, Hindustan Bio Sciences Ltd has a market capitalization of 9.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.79 Cr and a Net Profit of 0.10 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 0.80 Cr and Total Assets of 3.37 Cr.

How has been the historical performance of Hind.Bio Science?

Hind.Bio Science has experienced fluctuating financial performance, with net sales declining from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, though profitability metrics show signs of recovery, particularly with an operating profit margin improving to 12.35% in Mar'25. Total liabilities and assets have also decreased during this period, while cash flow from operations has remained stagnant.

Answer:<BR>The historical performance of Hind.Bio Science shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Hind.Bio Science's net sales have seen a decline from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, with a peak of 1.94 Cr in Mar'20 and a slight recovery to 1.03 Cr in Mar'24 before falling again. Total operating income followed a similar trajectory, peaking at 3.56 Cr in Mar'19 and dropping to 0.81 Cr in Mar'25. The company has consistently reported no raw material costs, while the purchase of finished goods decreased from 2.92 Cr in Mar'19 to 0.49 Cr in Mar'25. Operating profit margins have fluctuated significantly, with a negative margin of -127.27% in Mar'22 improving to 12.35% in Mar'25. Profit after tax also showed volatility, moving from 0.11 Cr in Mar'19 to a loss of -0.94 Cr in Mar'21, before recovering to 0.10 Cr in Mar'25. The total liabilities have decreased from 5.55 Cr in Mar'20 to 3.41 Cr in Mar'25, while total assets have also declined from 5.55 Cr to 3.41 Cr in the same period. Cash flow from operating activities has remained stagnant, with no cash inflow or outflow recorded in the last few years. Overall, Hind.Bio Science has experienced significant fluctuations in its financial performance, with recent signs of recovery in profitability metrics.

Is Hind.Bio Science overvalued or undervalued?

As of November 3, 2025, Hind.Bio Science is considered overvalued with a PE ratio of 54.70, significantly higher than its peers, and has underperformed the Sensex year-to-date, indicating a risky investment.

As of 3 November 2025, the valuation grade for Hind.Bio Science has moved from very expensive to risky. The company is currently considered overvalued. Key ratios include a PE ratio of 54.70, an EV to EBITDA of -10.08, and a PEG ratio of 0.82. <BR><BR>In comparison to its peers, Hind.Bio Science's PE ratio is significantly higher than Sun Pharma's 35.62 and Cipla's 22.44, indicating a premium valuation despite its negative earnings multiples. Additionally, while the stock has shown a strong return of 13.7% over the past week, it has underperformed the Sensex year-to-date, with a decline of 26.84%. Overall, these factors suggest that Hind.Bio Science is overvalued relative to its peers and financial metrics.

When is the next results date for Hindustan Bio Sciences Ltd?

The next results date for Hindustan Bio Sciences Ltd is 30 May 2026.

The next results date for Hindustan Bio Sciences Ltd is scheduled for 30 May 2026.

Should I buy, sell or hold Hindustan Bio Sciences Ltd?

Are Hindustan Bio Sciences Ltd latest results good or bad?

Hindustan Bio Sciences Ltd's latest results are concerning, showing a net loss of ₹0.12 crores and zero net sales in Q4 FY26, indicating significant operational challenges and revenue volatility. The company's return on equity has also decreased, and its stock has underperformed compared to the market.

The latest results for Hindustan Bio Sciences Ltd are concerning. In the fourth quarter of FY26, the company reported a net loss of ₹0.12 crores, a significant decline from a profit of ₹0.08 crores in the previous quarter. Additionally, net sales plummeted to zero, marking a 100% decline quarter-on-quarter. This pattern of alternating between quarters with zero revenue raises serious questions about the company's operational viability.<BR><BR>The company's return on equity has also decreased, with the latest figure at 8.60%, down from 14.00%. Over the past year, the stock has underperformed, declining by 17.23%, compared to an 8.82% drop in the Sensex.<BR><BR>Overall, the financial performance indicates a troubling trend of revenue volatility and operational challenges, suggesting that the company's current situation is quite poor. The lack of consistent sales and the absence of institutional investor confidence further highlight the difficulties Hindustan Bio Sciences is facing.

Why is Hindustan Bio Sciences Ltd falling/rising?

As of 02-Jun, Hindustan Bio Sciences Ltd's stock price is at 7.83, reflecting a decline of -4.74% and an overall drop of -8.95% over the last three days. Despite a year-to-date gain of +48.58%, the stock has underperformed recently, indicating short-term weakness and a longer-term downward trend.

As of 02-Jun, Hindustan Bio Sciences Ltd's stock price is falling, currently at 7.83, which reflects a change of -0.39 or -4.74%. The stock has been underperforming, having lost value for the last three consecutive days, resulting in a total decline of -8.95% during this period. Over the past week, the stock has decreased by -7.67%, significantly more than the benchmark Sensex, which fell by only -1.79%. <BR><BR>In terms of moving averages, the stock is currently higher than its 200-day moving average but lower than its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a short-term weakness. Additionally, despite a rise in investor participation, with delivery volume increasing by 147.85% against the 5-day average, the overall performance today has underperformed the sector by -4.06%. <BR><BR>Year-to-date, the stock has shown a positive return of +48.58%, but over the last year, it has declined by -19.69%, suggesting a longer-term trend of falling prices. Overall, these factors contribute to the current downward movement in the stock price of Hindustan Bio Sciences Ltd.

Which are the latest news on Hind.Bio Science?